Author

H. Shimizu

Observed names: H SHIMIZU, H Shimizu, H. SHIMIZU, Hidetoshi SHIMIZU, Hidetoshi Shimizu

Institution: Tanabe Pharma Corporation (Japan)

Observed institutions: RIKEN Center for Brain Science, Okazaki National Research Institutes, SPring-8, University of Tokyo Hospital, RIKEN, Ono Pharmaceutical (Japan), Ehime University, Tanabe Pharma Corporation (Japan), University of Göttingen, The University of Tokyo, Ludwig-Maximilians-Universität München, Tohoku Medical and Pharmaceutical University, Showa Pharmaceutical University, Osaka University of Pharmaceutical Sciences

ORCID: 0000-0002-4208-9790

Observed ORCID: 0000-0002-4208-9790

OpenAlex ID: A5021819365

Model studies on bimetallic Cu/Ru catalysts II. Adsorption of hydrogen

1980 · H SHIMIZU · Journal of Catalysis · 214

Stereochemical analysis of the methyl transfer catalyzed by cobalamin-dependent methionine synthase from Escherichia coli B

1986 · T. M. Zydowsky, L. F. Courtney, et al. · Journal of the American Chemical Society · 76

Bacterial luciferase activity and the intracellular redox pool in Escherichia coli

2005 · K. Koga, T. Harada, et al. · Molecular Genetics and Genomics · 44

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

2024 · Hidetoshi Shimizu, Michael A. Tortorici, et al. · Clinical and Translational Science · 39

PDF

Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults

2021 · Hidetoshi Shimizu, Yukiko Nishimura, et al. · Clinical Pharmacology in Drug Development · 36

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

2021 · Hidetoshi Shimizu, Yukiko Nishimura, et al. · Clinical Pharmacology in Drug Development · 32

Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals

2018 · Hidetoshi Shimizu, Kosuke Yoshida, et al. · Drug Metabolism and Disposition · 27

PDF

Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2

2018 · Ryo Sakakibara, Wataru Sasaki, et al. · Journal of Medicinal Chemistry · 24

Rapid enzymatic analysis of plasma for tyrosine

1990 · H Shimizu, K Taniguchi, et al. · Clinical Chemistry · 17

Structures of the SEp22 dodecamer, a Dps-like protein fromSalmonella entericasubsp.entericaserovar Enteritidis

2010 · Takanori Miyamoto, Yasuko Asahina, et al. · Acta Crystallographica Section F Structural Biology and Crystallization Communications · 15

PDF

Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis

2023 · Hidetoshi Shimizu, Yukiko Nishimura, et al. · Clinical Therapeutics · 14

PDF

Prediction of human pharmacokinetics for low‐clearance compounds using pharmacokinetic data from chimeric mice with humanized livers

2021 · Kosuke Yoshida, Yuki Doi, et al. · Clinical and Translational Science · 13

PDF

Ursodeoxycholic acid stimulates the formation of the bile canalicular network

2012 · Yuki Ikebuchi, Hidetoshi Shimizu, et al. · Biochemical Pharmacology · 12

Temperature-programmed desorption of positive ions and neutral molecules from alkali halide layers deposited on a metal surface

1996 · H. Kawano, S. Kamidoi, et al. · Applied Surface Science · 9

X-Ray Diffraction Patterns of Cuprous Acetate and Cupric Oxyacetate

1952 · H. Shimizu, S. Weller · Journal of the American Chemical Society · 8

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

2020 · Tadakatsu Nakamura, Hidetoshi Shimizu, et al. · Clinical Therapeutics · 7

A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects

2020 · Hidetoshi Shimizu, Shinsuke Inoue, et al. · Clinical Pharmacology in Drug Development · 6

PDF

Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study

2022 · Hidetoshi Shimizu, Yukiko Nishimura, et al. · Clinical Pharmacology in Drug Development · 5

PDF

Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model

2023 · Hiroaki Iijima, Hidetoshi Shimizu, et al. · Diabetes Therapy · 2

PDF

Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants

2022 · Hidetoshi Shimizu, Yukiko Nishimura, et al. · Clinical Therapeutics · 2

PDF

Crystal structure of native Trypanosoma cruzi dihydroorotate dehydrogenase

2006 · D.K. Inaoka, H. Shimizu, et al. · Worldwide Protein Data Bank · 2

Variation of pharmacokinetics after oral administration of slow-release metoprolol tablets and pharmacogenetic considerations.

1992 · H Shimizu, H Noguchi, et al. · PubMed · 2

Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase in complex with oxonate

2006 · D.K. Inaoka, H. Shimizu, et al. · Worldwide Protein Data Bank · 1

The Influence of food on the bioavailability of slow-release metoprolol tartrate 120mg tablet in healthy volunteers and serum protein binding of metoprolol.

1991 · Hidetoshi SHIMIZU, Hideyo NOGUCHI, et al. · Drug Metabolism and Pharmacokinetics · 1

PDF

Bioavailability of slow-release metoprolol tartrate 120mg tablet in comparison with conventional metoprolol tartrate 40mg tablets in healthy volunteers.

1991 · Hidetoshi SHIMIZU, Hideyo NOGUCHI, et al. · Drug Metabolism and Pharmacokinetics · 1

PDF

Works count: 48

Citation count: 609

H-index: 12

I10-index: 13